Navigation Links
Block & Leviton LLP Investigates ViroPharma Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Shire PLC.
Date:11/11/2013

BOSTON, Nov. 11, 2013 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of ViroPharma Inc. ("ViroPharma" or the "Company") (NASDAQ:   VPHM) concerning the proposed acquisition of the Company by U.K.-based company, Shire PLC ("Shire"), in a transaction valued at approximately $4.2 billion.  Under the terms of the transaction, Shire will acquire each ViroPharma share for $50.00, representing a paltry premium of 27% to ViroPharma's closing share price on Friday, November 8, 2013.   

The transaction was announced less than two weeks after ViroPharma announced highly positive third quarter 2013 financial results, which management described as an "extremely strong period of growth and positive momentum across our entire organization."  At that time, the Company also raised its North American net sales guidance to between $395 and $405 million. 

ViroPharma's share price has been spiking over the last year - trading between $22.12 per share on December 31, 2012 and hitting a high of $41.14 on November 7, 2013.  Indeed, in September 2013, the Company's share price rose nearly 30%.  The so-called premium appears to significantly undervalue the Company, especially considering that several companies, including Sanofi, were apparently interested in ViroPharma, which makes Cinryze for the treatment of immune disorder hereditary angioedema.  Treatments for such rare disorders can command huge prices, running into hundreds of thousands of dollars a year per patient.

Block & Leviton's investigation seeks to determine, among other things, whether ViroPharma's Directors breached their fiduciary duties by failing to maximize shareholder value in the proposed acquisition by Shire and the fairness by which the ViroPharma's Directors considered and approved the transaction.

If you are a ViroPharma shareholder and have questions about your legal rights, or if you have information relevant to this investigation, please contact attorney Steven P. Harte, at
(617) 398-5600 or email him at Steven@blockesq.com.  

Block & Leviton is a Boston-based law firm representing investors nationwide for violations of securities laws.  The firm's lawyers have collectively been prosecuting securities cases on behalf of investors for over 50 years.  This notice may constitute attorney advertising.

Contact:
BLOCK & LEVITON LLP
Steven P. Harte, Esq.
steven@blockesq.com
(617) 398-5600


'/>"/>
SOURCE Block & Leviton LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Too Much Sugar on the Menu? A New Tablet Might Someday Block Those Carbs
2. ACI: Drug and Medical Device Litigation Conference - Blockbuster Faculy Announced
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
5. UK Ministers to Block Law against Headshops
6. Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia
7. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
8. Stenting blocked bowel arteries saves lives
9. Blockbuster Expectations Dont Always Translate to Market Reality
10. Block Engineering Announces Collaborative Agreement with Pfizer for Next Generation Cleaning Verification Technology
11. Missouris PSE Blocking Technology Leading To Progress In Battle Against Meth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2019)... ... July 19, 2019 , ... Cloudticity, ... of Chris Whaley as Senior Vice President of Business Development. , Whaley ... experience better using cloud technology. , As a technology leader with more than ...
(Date:7/19/2019)... ... July 19, 2019 , ... Robinson Pharma, Inc., is proud to ... facilities was audited by the Safe Quality Food (SQF) Institute using an accredited certification ... Safety Code for Manufacturing, Edition 8. , The SQF Certification program is trusted by ...
(Date:7/18/2019)... ... July 18, 2019 , ... ComplianceLine, the ... 20 years, announced today it is moving into new corporate headquarters in Charlotte ... are thrilled to be moving into the new office which will allow our ...
Breaking Medicine Technology:
(Date:7/18/2019)... , ... July 18, 2019 , ... Gateway Genomics ... children, announces a new publication titled, “ Accurate Fetal Sex Determination from Maternal Blood ... In the study, DNA blood samples were collected from 108 women at an average ...
(Date:7/17/2019)... ... July 17, 2019 , ... The ... online Family Nurse Practitioner program. The honor is given to distance learning courses ... , The Catalyst Awards honor institutions from around the world that produce exemplary ...
(Date:7/17/2019)... SAINT PAUL, Minn. (PRWEB) , ... July 17, ... ... created to assist healthcare providers working with the ICD-10 coding set, is launching ... listeners Continuing Education Units (CEUs) at no additional charge, officials announced this week. ...
(Date:7/17/2019)... YORK (PRWEB) , ... July 17, 2019 , ... A ... the Journal of the American Medical Association (JAMA), shows for the first ... sepsis deaths in the state. Sepsis is the body’s extreme response to infection. It ...
(Date:7/17/2019)... ... , ... Dr. Jonathan Zaidan, MD, FACOG, President of Women’s Excellence discusses a ... The show airs on Wednesday, July 17ths at 7pm. The show podcast will ... Ann Thomas discuss the challenges that women face when it comes to weight loss ...
Breaking Medicine News(10 mins):